Indivior launched a copycat version of the opioid addiction drug Suboxone in the U.S., one day after a court decision cleared the way for rivals to market generic forms of the blockbuster medicine.

Tecentriq has lost market share to Merck & Co.’s rival Keytruda since a study showed Roche’s immunotherapy drug failed to improve overall survival in bladder cancer.

Novartis’ Zykadia drug performed well against a rare form of lung cancer, citing a study the Swiss company hopes will help it win expanded regulatory approval.

IMS analysis revealed that lower-cost copies of complex biotechnology drugs could save the United States and Europe’s five top markets as much as €98 billion ($110 billion) by 2020.

European and U.S. drug regulators are looking into whether a defective blood clotting test device affected a trial involving Bayer’s top-selling anti-clotting drug Xarelto, hitting the German drugmaker’s shares. The study compared Xarelto, also known as rivaroxaban, with older drug warfarin for preventing strokes in patients with a type of irregular heartbeat common among the […]